Unsolicited reports of the wearing-off effect related to ocrelizumab were infrequent (< 2%).
People with multiple sclerosis who took part in a structured, 4-step therapeutic patient education program exhibited improved mental quality of life, better understanding of their disease, and reduced anxiety and depression.